Antiestrogens upregulate estrogen receptor beta expression and inhibit adrenocortical H295R cell proliferation.
The molecular mechanisms involved in adrenocortical tumorigenesis are still not completely understood. In this study, using the H295R cell line as a model system, we investigated the role of estrogens and estrogen receptor (ER) alpha and ER beta in the growth regulation of adrenocortical tumors. We demonstrated that H295R cells are able to convert androgens to estrogens by a constitutive expression of active cytochrome P450 aromatase protein and express ER beta to a greater extent than ER alpha. Moreover, physiological concentrations of 17beta-estradiol (E2) determined an increase of thymidine incorporation, suggesting the presence of an autocrine mechanism in maintaining H295R cell proliferation. Evaluating the response to ER antagonists like 4-hydroxytamoxifen (OHT) and ICI 182 780 (ICI), we observed an up-regulation of ER beta and a dose-dependent inhibition of H295R cell proliferation. Whereas ICI determined the growth arrest of H295R cells, OHT induced morphological changes that were characteristic of apoptosis. According to the above-mentioned observations, OHT but not ICI clearly induced a marked expression of FasL and the cleavage of both caspase-8 and caspase-3. Interestingly, the apoptotic effects of OHT in H295R cells may be consequent to the enhanced levels of ER beta which stimulate the expression of FasL interacting with activating protein (AP)-1 sites located within its promoter sequence. In conclusion, we have demonstrated that H295R cells are able to transform androgens to estrogens that activate an autocrine mechanism, mediated by their own receptors, and contribute to regulate the proliferation of these cells. Moreover, this study points towards a role for ER beta as an important mediator of the repressive effects exerted by antiestrogens on H295R cells; however, further studies are needed to clarify its role in the control of adrenocortical cell proliferation and on the potential benefits of antiestrogens for treatment of adrenocortical cancer.
Montanaro
D
D
Department of Pharmaco-Biology, University of Calabria, 87036 Arcavacata di Rende (CS), Italy.
Maggiolini
M
M
Recchia
A G
AG
Sirianni
R
R
Aquila
S
S
Barzon
L
L
Fallo
F
F
Andò
S
S
Pezzi
V
V
D000302:Adrenal Cortex / Q000166:cytology* / Q000473:pathology; D000306:Adrenal Cortex Neoplasms / Q000378:metabolism / Q000473:pathology; D000728:Androgens / Q000378:metabolism; D017209:Apoptosis; D001141:Aromatase / Q000378:metabolism; D047072:Aromatase Inhibitors / Q000378:metabolism; D019898:Autocrine Communication; D020169:Caspases / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005576:Colforsin / Q000378:metabolism; D004958:Estradiol / Q000378:metabolism; D020847:Estrogen Receptor Modulators / Q000378:metabolism*; D047628:Estrogen Receptor alpha / Q000235:genetics / Q000378:metabolism; D047629:Estrogen Receptor beta / Q000235:genetics / Q000378:metabolism*; D053222:Fas Ligand Protein; D006801:Humans; D000077289:Letrozole; D008562:Membrane Glycoproteins / Q000235:genetics / Q000378:metabolism; D009570:Nitriles / Q000378:metabolism; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000378:metabolism; D014230:Triazoles / Q000378:metabolism; D048069:Tumor Necrosis Factors / Q000235:genetics / Q000378:metabolism; D019014:fas Receptor / Q000378:metabolism
D000728:Androgens; D047072:Aromatase Inhibitors; D020847:Estrogen Receptor Modulators; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D009570:Nitriles; D012333:RNA, Messenger; D014230:Triazoles; D048069:Tumor Necrosis Factors; D019014:fas Receptor; D005576:Colforsin; D004958:Estradiol; D000077289:Letrozole; D001141:Aromatase; D020169:Caspases